Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Makes organizational and executive changes
June 2, 2014
By: Kristin Brooks
Teva Pharmaceutical Industries Ltd. has made several new organizational structure and related executive changes, which will become effective July 1. All of Teva’s business units will be aligned to accelerate its operational network transformation and integration. “The new organizational structure and leadership team will better position Teva to deliver sustainable growth and create short and long-term value. We must capitalize first on our existing assets and capabilities, and exploit opportunities and synergies emanating from the full integration of all business activities – most importantly, generic and specialty – while leveraging our global R&D and operations capabilities,” said Teva’s president and chief executive officer, Erez Vigodman. Teva will be headed by two commercial business units, Global Specialty Medicines (GSM) and the newly-formed Global Generic Medicines group (GGM). GGM will have full global responsibility for all existing generic markets, including portfolio management and selection, product launch, and commercial execution. GGM will also be responsible for Teva’s OTC business, led by its joint venture with The Procter and Gamble Co. Sigurdur Olafsson has been appointed president and chief executive officer of GGM and will be based in the U.S. Mr. Olafsson brings more than 20 years of diverse experience as a pharma industry executive serving in a number of leadership roles, including his previous role as president of Actavis Pharma. The GSM group, led by Dr. Rob Koremans, is responsible for Teva’s global specialty medicines business. Both the GGM and GSM units will work together to create synergies and leverage Teva’s product portfolio in both its innovative and generics businesses. The newly formed Corporate Development, Strategy and Innovation Group will continue to be responsible for strategy and business development initiatives, and also look for innovative business models, partnerships and technologies. A group leader has not yet been appointed. Teva is creating a new Global Corporate Marketing Excellence and Communications Group, which will be responsible for corporate marketing, brand management, corporate communications and corporate social responsibility. Iris Beck-Codner has been appointed executive vice president of the group. Eric Drapé, currently the head of Sterile, Respiratory and Specialty Operations has been named executive vice president, global head of the Quality Group. Mr. Drapé will report directly Teva’s president and chief executive officer, Erez Vigodman, and will work in close collaboration with Dr. Carlo De Notaristefani, president and chief executive officer of Teva’s Global Operations. Eyal Desheh, Teva’s executive vice president and chief financial officer, will also be responsible for Teva’s corporate efficiency program and will continue to oversee Global IT, and will assume joint responsibility for Investor Relations, with Mr. Vigodman. “The new, fully integrated commercial generic business, under the leadership of Sigurdur Olafsson, is designed to enhance Teva’s current leadership position in the global generic market. The unified generic business will focus on accelerating business growth, achieving competitive costs, developing innovative value propositions, creating a broad and differentiated portfolio, and strengthening our commercial position in all existing markets,” said Mr. Vigodman. “Siggi brings with him a wealth of experience and knowledge obtained through a series of leadership positions in the pharmaceutical industry. He has consistently demonstrated his ability to lead complex business initiatives, which generate significant value. We are fortunate to have him join our team and I am confident in his ability to take our global generic business to the next level.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !